FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors  PR NewswireEuropean Medicines Agency Issues Positive Opinion for Concizumab Label Update in Hemophilia  Docwire NewsNovo Nordisk’s Alhemo Recommended for Expanded Use in Europe for Haemophilia A and B  MSNFDA approves concizumab-mtci for hemophilia A/B without inhibitors in patients 12 years and older  Contemporary PediatricsAlhemo®’s FDA Approval for Hemophilia A/B Without Inhibitors: A Game-Changer for Novo Nordisk’s Rare Disease Portfolio  AInvest